Endoscopic therapies for Barrett's-associated dysplasia: A new paradigm for a new decade

Sri Komanduri*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The emergence of endoscopic therapies for Barrett's esophagus (BE)-associated dysplasia has significantly altered the management of this complex disease. Over the past decade, there has been a paradigm shift from that of pure surveillance to a more therapeutic approach in eradicating dysplastic BE. This strategy includes less invasive options than esophagectomy for high-grade dysplasia and early eradication of confirmed low-grade dysplasia. Although multiple modalities exist for endoscopic therapy, endoscopic mucosal resection coupled with radiofrequency ablation appears to be the most effective therapy, with minimal complications. Recent advances in endoscopic eradication therapies for dysplastic BE have fueled excitement for a significant weapon against the rising incidence of esophageal cancer.

Original languageEnglish (US)
Pages (from-to)291-300
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Issue number3
StatePublished - Jun 2012


  • Barrett's esophagus
  • ablation
  • endoscopic mucosal resection
  • esophageal cancer
  • gastroesophageal reflux
  • radiofrequency

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Endoscopic therapies for Barrett's-associated dysplasia: A new paradigm for a new decade'. Together they form a unique fingerprint.

Cite this